A Phase Ib/II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients With Metastatic Non-small Cell Lung Cancer After Progression on First-Line Systemic Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
Phase of Trial: Phase I/II
Latest Information Update: 27 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary) ; PGG-glucan (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biothera
- 19 Jul 2017 According to a Biothera Pharmaceuticals media release, patient dosing has commenced in this trial.
- 22 Dec 2016 Status changed from planning to recruiting.
- 24 Aug 2016 According to a Biothera Pharmaceuticals media release, this trial is likely to initiate in Fall 2016.